Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 3/2015

01-09-2015 | Original Research

Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma

Authors: Mitra Khalili, Mohammad Vasei, Davood Khalili, Kamran Alimoghaddam, Majid Sadeghizadeh, Seyed Javad Mowla

Published in: Journal of Gastrointestinal Cancer | Issue 3/2015

Login to get access

Abstract

Purpose

Many cell signaling pathways essential for normal stem cell development are involved in cancer initiation and progression. In the present study, motivated by a possible contribution of reprogramming process in induction of cancer, we compared the expression level of main genes involved in iPS generation, i.e., miR-302, miR-145, SOX2, c-MYC, and P21, in a series of tumor and non-tumor tissues of stomach.

Methods

A total number of 34 tumors and their matched non-tumor (as control) gastric surgical specimens were obtained. The expression of the candidate genes was evaluated by using real-time PCR and immunohistochemistry (IHC) techniques.

Results

Our data revealed a significant downregulation of miR-302b, P21, and miR-145 genes in intestinal and SOX2 gene in diffuse type of tumor samples. SOX2, but not the other genes, showed a significant downregulation in both proximal (cardia and fundus) and distal (body and antrum) sites of stomach. Based on receiver-operating characteristic (ROC) analyses, the highest total area under the curve (AUC) was found for SOX2 (AUC = 82 %, P < 0.001). Interestingly, all tumor samples revealed a negative signal for c-MYC expression, while non-tumor samples represented an intense cytoplasmic staining.

Conclusions

Despite the fact that some hESC-specific genes are upregulated in tumors, our data revealed a significant downregulation of all candidate genes, except for c-MYC, in tumor samples of stomach. Moreover, ROC data demonstrated that SOX2 gene expression index is a better potential biomarker of gastric cancer, compared to other tested genes. SOX2 expression has a good sensitivity and specificity to discriminate correctly between tumor/non-tumor and also high/low grades of tumor malignancy. It seems downregulation of miR-302b, miR-145, and P21 could contribute to gastric tumor initiation and progression.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268–77.PubMedCrossRef Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268–77.PubMedCrossRef
6.
go back to reference Barroso-del Jesus A, Lucena-Aguilar G, Menendez P. The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle. 2009;8(3):394–8.PubMedCrossRef Barroso-del Jesus A, Lucena-Aguilar G, Menendez P. The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle. 2009;8(3):394–8.PubMedCrossRef
7.
go back to reference Barroso-delJesus A et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol. 2008;28(21):6609–19.PubMedCentralPubMedCrossRef Barroso-delJesus A et al. Embryonic stem cell-specific miR302-367 cluster: human gene structure and functional characterization of its core promoter. Mol Cell Biol. 2008;28(21):6609–19.PubMedCentralPubMedCrossRef
8.
go back to reference Card DA et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol. 2008;28(20):6426–38.PubMedCrossRef Card DA et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol. 2008;28(20):6426–38.PubMedCrossRef
9.
go back to reference Xu N et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647–58.PubMedCrossRef Xu N et al. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647–58.PubMedCrossRef
10.
go back to reference Gao P et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013;32(4):491–501.PubMedCrossRef Gao P et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013;32(4):491–501.PubMedCrossRef
11.
go back to reference Xing AY et al. Deregulated expression of miR-145 in manifold human cancer cells. Exp Mol Pathol. 2013;95(1):91–7.PubMedCrossRef Xing AY et al. Deregulated expression of miR-145 in manifold human cancer cells. Exp Mol Pathol. 2013;95(1):91–7.PubMedCrossRef
15.
go back to reference Aloni-Grinstein R, et al. The barrier to cancer stem cell formation. FEBS Lett. 2014; 53. Aloni-Grinstein R, et al. The barrier to cancer stem cell formation. FEBS Lett. 2014; 53.
17.
go back to reference Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
18.
go back to reference Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. Acta Pathol Jpn. 1982;32 Suppl 2:329–47.PubMed Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. Acta Pathol Jpn. 1982;32 Suppl 2:329–47.PubMed
19.
go back to reference Pfaffl M. Relative quantification. In: Dorak MT, editor. Real-time PCR, vol. 63. New York: Taylor and Francis Group; 2006. p. 63–82. Pfaffl M. Relative quantification. In: Dorak MT, editor. Real-time PCR, vol. 63. New York: Taylor and Francis Group; 2006. p. 63–82.
20.
go back to reference Li XL et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 2004;24(2):257–63.PubMed Li XL et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 2004;24(2):257–63.PubMed
21.
go back to reference Otsubo T et al. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 2008;98(4):824–31.PubMedCentralPubMedCrossRef Otsubo T et al. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 2008;98(4):824–31.PubMedCentralPubMedCrossRef
22.
go back to reference Zhang X et al. SOX2 in gastric carcinoma, but not Hath1, is related to patients’ clinicopathological features and prognosis. J Gastrointest Surg. 2010;14(8):1220–6.PubMedCrossRef Zhang X et al. SOX2 in gastric carcinoma, but not Hath1, is related to patients’ clinicopathological features and prognosis. J Gastrointest Surg. 2010;14(8):1220–6.PubMedCrossRef
23.
go back to reference Bornschein J et al. Dysregulation of CDX1, CDX2 and SOX2 in patients with gastric cancer also affects the non-malignant mucosa. J Clin Pathol. 2013;66(9):819–22.PubMedCrossRef Bornschein J et al. Dysregulation of CDX1, CDX2 and SOX2 in patients with gastric cancer also affects the non-malignant mucosa. J Clin Pathol. 2013;66(9):819–22.PubMedCrossRef
24.
go back to reference Matsuoka J et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 2012;174(1):130–5.PubMedCrossRef Matsuoka J et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 2012;174(1):130–5.PubMedCrossRef
25.
go back to reference Hutz K, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014. Hutz K, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014.
26.
go back to reference Cai N, Wang YD, Zheng PS. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA. 2013;19(1):85–95.PubMedCentralPubMedCrossRef Cai N, Wang YD, Zheng PS. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA. 2013;19(1):85–95.PubMedCentralPubMedCrossRef
27.
go back to reference Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 2010;70(22):9473--82. Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 2010;70(22):9473--82.
28.
go back to reference Wang L et al. MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer. 2013;13:448.PubMedCentralPubMedCrossRef Wang L et al. MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer. 2013;13:448.PubMedCentralPubMedCrossRef
29.
go back to reference Yan GJ et al. MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1. Cancer Lett. 2014;345(1):39–47.PubMedCrossRef Yan GJ et al. MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1. Cancer Lett. 2014;345(1):39–47.PubMedCrossRef
30.
go back to reference Tabrizi M, Khalili M, Vasei M, Nouraei N, Mansour Samaei N, Khavanin A, Khajehei M, Mowla SJ. Evaluating the miR-302b and miR-145 Expression in Formalin-Fixed Paraffin-Embedded Samples of Esophageal Squamous Cell Carcinoma. Arch Iran Med. 2015 Mar;18(3):173–8. Tabrizi M, Khalili M, Vasei M, Nouraei N, Mansour Samaei N, Khavanin A, Khajehei M, Mowla SJ. Evaluating the miR-302b and miR-145 Expression in Formalin-Fixed Paraffin-Embedded Samples of Esophageal Squamous Cell Carcinoma. Arch Iran Med. 2015 Mar;18(3):173–8.
32.
go back to reference Geisler JP et al. Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival. Int J Gynecol Cancer. 2004;14(1):133–7.PubMedCrossRef Geisler JP et al. Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival. Int J Gynecol Cancer. 2004;14(1):133–7.PubMedCrossRef
Metadata
Title
Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma
Authors
Mitra Khalili
Mohammad Vasei
Davood Khalili
Kamran Alimoghaddam
Majid Sadeghizadeh
Seyed Javad Mowla
Publication date
01-09-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 3/2015
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9695-2

Other articles of this Issue 3/2015

Journal of Gastrointestinal Cancer 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.